The economics of the public option evidence from local pharmaceutical markets Juan Pablo Atal, José Ignacio Cuesta, Felipe González and Cristóbal Otero
Contributor(s): Atal, Juan Pablo
.
Material type: 






Item type | Current location | Home library | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Artículos | IEF | IEF | OP 234/2024/3-1 (Browse shelf) | Available | OP 234/2024/3-1 |
Browsing IEF Shelves Close shelf browser
No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | ||
OP 234/2024/12-2 Loans for the "Little Fellow" | OP 234/2024/2 The American Economic Review | OP 234/2024/3 The American Economic Review | OP 234/2024/3-1 The economics of the public option | OP 234/2024/3-2 The effect of macroeconomic uncertainty on household spending | OP 234/2024/4 The American Economic Review | OP 234/2024/4-1 The opportunity cost of debt aversion |
Resumen.
Bibliografía.
We study the effects of competition by state-owned firms, leveraging the decentralized entry of public pharmacies to local markets in Chile. Public pharmacies sell the same drugs at a third of private pharmacy prices, because of stronger upstream bargaining and market power in the private sector, but are of lower quality. Public pharmacies induced market segmentation and price increases in the private sector, which benefited the switchers to the public option but harmed the stayers. The countrywide entry of public pharmacies would reduce yearly consumer drug expenditure by 1.6 percent.
There are no comments for this item.